Group items tagged

The Department of Health and Social Care (DHSC) has announced adjustments to the reimbursement rates for several Aptamil products dispensed earlier this year, following a pricing error that left pharmacies out of pocket. The changes, which apply to products dispensed between January and April 2024, come after Community Pharmacy England (CPE) raised concerns about discrepancies in the pricing data used by the NHS. The issue stemmed from recent price increases by Nutricia Ltd, the manufacturer of Aptamil, which were not reflected in the NHS Dictionary of Medicines and Devices (dm+d). To address the shortfall, the DHSC has retrospectively increased the reimbursement prices for the following Aptamil products: - Aptamil Anti-Reflux powder (800g): From £14.29 to £16.08 - Aptamil Comfort milk (800g): From £14.29 to £16.08 - Aptamil First milk powder (200ml): From £0.92 to £1.06 - Aptamil Follow On milk (200ml): From £0.92 to £1.06 - Aptamil Lactose Free powder (400g): From £7.70 to £8.39 These changes, effective from January 2024, are intended to ensure that pharmacies are appropriately reimbursed for the cost of these products.

The number of people suffering from addiction is at an all time high, with more people seeking treatment across the USA due to the fentanyl crisis, but new studies have shown that addiction drugs may not only be able to aid those suffering from the deadly disease, but also aid people suffering from long COVID. While there has long been research underway to find a cure for the likes of alcoholism and drug addiction, it turns out naltrexone, a drug used in the addiction treatment space, is helping people who have been suffering from headaches, seizures and fatigue as a result of long COVID. According to Dr. Paul Valbuena at The River Source, an Arizona drug rehab, naltrexone is typically used by rehab centers and prescribed to patients suffering from addiction to reduce cravings and the feeling of euphoria associated with substance use disorder, giving patients clarity and focus to concentrate on recovery. Thanks to a recent report, that has also been revealed to be the case for those suffering with long COVID too, with Lauren Nichols, a long COVID sufferer from Chicago being prescribed the drug by her doctor. She found that the drug helped quell her seizures and headaches, alowing her to think clearly and get on with her life as normal. It's been a similar story for other patients too, and has marked a major breakthrough in the bid to help those who are still suffering in the aftermath of the pandemic.

The Department of Health and Social Care (DHSC) has invited views of healthcare professionals and others to tackle the six major health conditions which drive-ill health and contribute to the burden of disease in England. The six major health conditions - cancer; cardiovascular diseases including stroke and diabetes; chronic respiratory diseases; dementia; mental ill-health and musculoskeletal disorders - affect millions of people in England with data showing that one in four suffer from two or more of these major long-term conditions. Recognising the pressure these conditions are putting on the NHS, the government is seeking views on a new strategy to tackle them that will focus not only on treatment but also on prevention. Government is particularly interested in hearing from those who suffer from, care for or provide treatment to people who suffer from multiple long-term conditions. This is to ensure the Major Conditions Strategy is one that will better prevent, diagnose, manage and treat these conditions. Contributions are also encouraged from those working in NHS bodies, local government, the voluntary and community sector, and wider industry, on how best to tackle suffering from one or more of these major conditions. Particularly, it is seeking perspectives on how government and the NHS can work better together with different organisations and sectors to improve the nation's health.

The European Union's population shrank for a second year running last year, the bloc's statistics office said on Monday, as the region reels from over two million deaths from the coronavirus. According to Eurostat, the population of the 27 countries that make up the bloc fell by close to 172,000 from the previous year and over 656,000 from January 2020. "In 2020 and 2021 the positive net migration no longer compensated for the negative natural change in the EU and, as a consequence, the EU total population has been decreasing," it said, pointing to impacts from the pandemic. The number of deaths began outstripping births in the EU a decade ago, but immigration from outside the bloc helped offset the gap until the first year of the pandemic. The previous time the EU had registered a fall in population was in 2011 - the only other time since 1960 - but this rapidly picked up due to net migration.

A new report published by the NHS Business Services Authority (NHSBSA) reveals that 24,300 dentists performed NHS dental activity in England in 2023/24, marking a 0.4 per cent rise from the previous year's 24,227. However, this figure represents a 1.5 per cent decrease from 24,700 dentists with NHS activity in 2019/20. The report covers NHS dental activity and the NHS dental workforce in England from 2019/20 to 2023/24. It is the first release from NHSBSA following the transition from NHS England, which previously issued the report. There were 34 million courses of dental treatment in England for 2023/24, a 4.3 per cent increase from 2022/23. The total units of dental activity (UDAs) rose by 3.4 per cent to 73 million.

Prime minister Boris Johnson announced on Wednesday (January 19) that restrictions re-imposed in England last month would be lifted by from next Thursday (January 27). In the latest development, the government has decided to end the guidance on working from home, asking employers to make adequate arrangements to return safely to work. From the start of next Thursday, mandatory certification based on vaccines and tests will end, however, organisations can still choose to use the NHS Covid Pass voluntarily. Besides, the legal mandate to wear face masks will go away from next week. Making a statement to the House of Commons on Covid-19, he said that infection levels are falling in England mainly because of the country's "extraordinary booster campaign". He noted more than 36 million Covid-19 booster jabs had been delivered, with over 90 percent of over-60s now given a third dose. "Our scientists believe it is likely that the Omicron wave has now peaked nationally," Johnson added, while cautioning "the pandemic is not over". "I encourage everyone across the country to continue with all the cautious behaviours that we know help to keep each everybody safe."

Panadol launched a new purpose-led brand idea as part of a multi-channel campaign across Great Britain and Ireland. With nine out of 10 people suffering "everyday pain" and 65% of people saying they can't be happy when they are in pain[1], globally, the campaign reiterates the brand's commitment to holistic pain management by focusing on the acute pain recovery journey. Rooted in deep consumer understanding, the campaign idea celebrates that never-talked-about moment of realisation when you start to feel the release from pain. The new brand idea will bring to life the emotional transformation that those suffering from acute pain undergo, emphasising the role that Panadol can play in alleviating their pain. The Panadol campaign follows a period of strong sales growth for the brand, outperforming the category's own expansion by more than double[2]. This has been driven by shoppers who are searching for fast and effective pain relief products, such as Panadol's hero variants, including Panadol Extra Advance Tablets (paracetamol, caffeine), which has seen its growth almost doubled[3], as well as Panadol Advance Tablets (paracetamol) and Panadol Extra Advance Tablets. Monica Michalopoulou, GBI Marketing Director, said: "After two years of pandemic restrictions, now more than ever, people want to get back to their normal lives and to the people they love. But with pain preventing many of us from connecting with those we love or from doing the things we enjoy the most, we want to help consumers by understanding their pain journey and reassuring them on the treatments we can provide. This "Release" moment is so important for pain sufferers, and we hope our new brand campaign can shine a light on the role that Panadol can play in pain relief".

Women in the UK will be able to purchase Gina 10 mg vaginal tablets without prescription from September from their local pharmacies, announced the Medicines and Healthcare products Regulatory Agency (MHRA). The Hormone Replacement Therapy (HRT) product, Gina 10 microgram vaginal tablets (containing estradiol) are used for the treatment of vaginal symptoms such as dryness, soreness, itching, burning and uncomfortable sex caused by oestrogen deficiency in postmenopausal women aged 50 years and above who have not had a period for at least one year. The decision to reclassify these vaginal tablets follows a safety review by the MHRA, independent advice from the Commission on Human Medicines (CHM), and a public consultation. The UK regulator sought views from patients, pharmacists, prescribers and a wide range of stakeholders including the Royal College of Obstetricians & Gynaecologists, the Faculty of Sexual & Reproductive Healthcare, the British Pharmacopoeia Commission and the British Menopause Society.

The General Pharmaceutical Council (GPhC) has proposed a 7.5 per cent increase in all fees for pharmacies, pharmacists, pharmacy technicians, and foundation trainees, including those for registration and renewal from April 2024. According to the GPhC's proposal the pharmacist renewal fee would increase by £19 from £257 to £276; the pharmacy technician renewal fee would increase by £9 from £121 to £130 and the pharmacy premises renewal fee would increase by £27 from £365 to £392 Any changes would be effective from April 2024, which means fees will remain at current levels for this financial year, giving registrants and applicants time to prepare for any increase in subsequent years. Fees have been frozen for the last two years (2022 and 2023) to help reduce pressure on both pharmacy professionals and pharmacy owners. Chief Executive, Duncan Rudkin, said: "In the last few years, we have been able to avoid raising many of these fees by improving our efficiency and by using our financial reserves to cover any gap between our income and our outgoings. While we are continuing to look for ways to make savings, we now have to consider increasing fees.

During the coronavirus pandemic many people found themselves working from home, and this has continued to some extent in many businesses. A change in working environment can bring challenges, one of which can be joint pain and discomfort. Imagine you have gone from a busy office environment, meeting in boardrooms and visiting the canteen for a coffee, to working at home on your dining room table, walking several feet to get a cup of tea and sitting back down again, this change in surroundings can have an impact on your joints. Community pharmacists can be a source of knowledge to help individuals that may be suffering from joint complaints, this may be from the above scenario or just general aches and pains that come from an office based role. Firstly, it's important for us to know the effects of sitting down at a desk all day (not a scenario I'm sure many community pharmacists experience daily): Back pain - is one of the most common complaints. This can be caused by bad posture while sitting too high, too low, or hunched over. While this may present as just a soreness or discomfort, if not rectified and/or accessed this can lead to some serious health issues such as spinal compression, sciatica or spinal stenosis.

Department of Health and Social Care (DHSC) has increased the rate of discount deduction for generics from 17.52 per cent to 20 per cent. The Drug Tariff for April 2023 will contain changes to the discount deduction arrangements for pharmacy contractors, which will include- all concession lines to be considered as Group Items for Discount Not Deducted i.e. DND or zero discount (ZD) items; and rate of discount deduction for generics to increase from 17.52% to 20% The Pharmaceutical Services Negotiating Committee (PSNC) and DHSC agreed on the changes for all concession lines to be considered as Group Items for Discount Not Deducted. Therefore from 1 April 2023, a new category will be introduced into Part II of the Drug Tariff 'Drugs for which discount is not deducted'. However, the committee had rejected the changes in the rate of discount deduction for generics. It said, "Following pressure from NHS England, Ministers have now chosen to impose changes to the previously agreed discount deduction arrangements, which come into effect from 1 April, and will be kept under review."

The latest findings from the National Cancer Patient Experience Survey 2022 by QualityWatch, a joint programme with the Nuffield Trust and the Health Foundation shed light on concerning disparities faced by ethnic minority communities in the UK healthcare system. Despite strides in cancer care, the survey highlights persistent challenges in easy and equitable access to timely diagnosis and quality communication, particularly for individuals from Mixed, Black, or Asian backgrounds. Key insights from the survey underscored that individuals from ethnic minority groups often require a higher number of interactions with healthcare professionals before receiving a cancer diagnosis. Notably, one in three people from Mixed, Black, or Asian ethnicities needed three or more visits to a GP practice, compared to the average of one in five across the population. These delays in diagnosis can have significant implications for treatment outcomes and overall patient experience. Moreover, the survey revealed concerning trends regarding the quality of communication following a cancer diagnosis among ethnic minority patients.

Community pharmacy is stuck in a vicious circle. Pharmacies are closing at an alarming rate whilst the government is talking about moving care away from hospitals and into the community to focus on preventative care. While the government talks about this vision for the future, the stark reality is that pharmacies are already struggling to meet the current Pharmacy First thresholds. And now we discover that one of the key components that could create capacity in pharmacy to deliver more clinical services has been put on hold…indefinitely. The recently published Darzi review, which was commissioned after the new government came to power to assess the state of the NHS, praised the value of community pharmacies and preventative services. But it recognised the level of pharmacy closures across the country and warned pharmacy access could be 'at risk'. Community pharmacy is ideally placed to deliver the government's vision of preventative care in the community. But let's all be clear, moving preventative services into community pharmacies has, so far, been nowhere near as successful as it could have been due to the current climate pharmacies find themselves in. The Pharmacy First scheme is a testament to this. Just this week it was announced that consultation thresholds for the Pharmacy First scheme have been reduced from 30 consultations to 20. It's the second time in three months that the thresholds have been reduced and it follows an intervention from Community Pharmacy England who wanted to "save many pharmacies from missing out on a vital payment this month." In June alone, 3,269 participating pharmacies failed to meet the threshold - that's almost a third of all community pharmacies in England.

A new study published in BMJ Open journal has revealed a significant decline in the number of general practices in England over the past decade, alongside shifts in workforce dynamics and organisational structures. Conducted by researchers from University College London (UCL) and the London School of Hygiene and Tropical Medicine (LSHTM), the study analysed data from NHS England, the Office for Health Improvement and Disparities, and the Care Quality Commission (CQC). They found that, between April 2013 and April 2023, the total number of general practices fell by 20 per cent, dropping from 8,044 to 6,419-an average loss of 178 practices per year. The decline coincided with an 11 per cent increase in the total population registered with a GP practice, which saw average practice list sizes swell by 40 per cent from 6,967 to 9,724 patients. Additionally, the number of unique practice postcodes decreased from 7163 to 5849, representing the loss of 18 per cent practice locations over this period.

The Royal College of Nursing (RCN) is calling for scrapping unfair benefit rules for migrant nursing staff, warning that these policies risk triggering a mass exodus from the UK's healthcare workforce. A recent RCN report indicated that two-thirds of internationally educated nursing staff are considering leaving the UK and returning to their country of training due to the high cost of living. The report, which is based on survey responses from more than 3,000 international nursing staff, also revealed that those from overseas are "twice as likely as domestic colleagues to report being in financial difficulty" and are "almost three times as likely as UK counterparts to withdraw from their pension due to the cost of living." It also highlighted the impact of the 'no recourse to public funds' (NRPF) rule, which prevents migrants on temporary visas, such as the Health and Care Worker visa, from accessing essential benefits. In response to this report, the union has urged the government to immediately end these restrictive rules and reduce visa fees, including Indefinite Leave to Remain (ILR) application costs.

The UK Covid-19 Inquiry has published the first record from Every Story Matters, bringing together stories from 50,000 people who have shared their experiences of life during the pandemic. Every Story Matters - the largest public engagement exercise ever undertaken by a UK inquiry - has been traveling across the UK to hear from the public since October 2023. These anonymised stories will help produce a themed report, which will help the Chair, Baroness Hallett, to reach conclusions and make recommendations for the future. Ben Connah, Secretary to the UK Covid-19 Inquiry, expressed his gratitude for the public's involvement, stating: "This is a remarkable milestone for the UK Covid-19 Inquiry and I could not be more grateful to the public for your support and involvement." "This year we have travelled the length and breadth of the UK to listen to people's stories, from Enniskillen to Ipswich, from Oban to Southampton. "Every one of these stories matters and will go on to shape the Chair's recommendations for the future."

A new report has highlighted that while NHS trusts are well placed to drive the new Labour government's desired healthcare transformation, additional resources are essential to fully realise this vision. Published by NHS Providers, the report explored how trusts are innovating and adapting to deliver the three key shifts outlined by the government: from hospital to community-based cafe, from analogue to digital, and from treatment to prevention. Titled "Providers Deliver: shifting care upstream," the report cited some successful approaches trusts have taken to ensure patients can get the care they need in the right place at the right time. Examples include: Tackling the wider determinants of health to improve patient flow - Hampshire and Isle of Wight Healthcare NHS Foundation Trust Reducing demand for emergency care by providing support at home - East Lancashire Hospitals NHS Trust Improving mental health crisis care from the ground up - North Staffordshire Combined Healthcare NHS Trust Harnessing a culture of continuous improvement to deliver care in the right place - Walsall Healthcare NHS Trust Taking the next step from hospital at home to early intervention - Hertfordshire Community NHS Trust

From July 2022, Manage Your Services (MYS) portal will be the only route available for pharmacy contactors to submit all new prescription returns/referred back items and disallowed items, reminded the Pharmaceutical Services Negotiating Committee (PSNC). Contractors will be able to view and submit the required information for all these items only through the MYS portal. The NHS Business Services Authority (NHSBSA) will send out a notification email from July (for the dispensing month of June) to the pharmacy NHSmail account if any new referred back or disallowed items have been generated for the contractor to complete on their MYS account. "Contractors can view any referred back items for completion by checking the 'Unpaid items' tab on MYS landing page," PSNC. "It is important to note that prescription returns/referred back items via MYS are only held in the system for a period of 18 months from the date they are first sent to the pharmacy for action; if contractors have not completed and returned any outstanding referred backs before this deadline has passed, the referred back items will be deleted from system."

The General Pharmaceutical Council (GPhC) has decided to increase the renewal fees of pharmacists, pharmacy technicians, and pharmacy premises by 7.5% from April 2024. The pharmacy technician's renewal fee will see an increase by £9 from £121 to £130, pharmacists fees from £257 to £276, and pharmacy premises from £365 to £392. The following decision came even despite the renewal fees being frozen for individual registrants since 2019 and for pharmacy premises since 2021. This move was facilitated through cost savings measures like using financial reserves and downsizing to a smaller office. However, the council confirmed that the fee hike is due to higher rates of inflation, increase in utility bills and supplier costs. Duncan Rudkin, Chief Executive and Registrar of the GPhC, said: "We know that these are challenging times and that this increase will come as unwelcome news to those we regulate. But to be effective in our role of protecting the public we need to make sure the fees we charge cover the cost of regulation going forward."

The results of a national NHS staff survey, published recently, revealed that frontline healthcare workers are facing record levels of discrimination at work, with 58,000 respondents reporting that they experienced "unacceptable" levels of unwanted sexual behaviour from the public last year. Concerningly, 8.67 per cent of 675,140 NHS workers who responded to the poll said they suffered sexual harassment from patients, patients' relatives, or other members of the public in 2023. Particularly, ambulance staff were affected, with nearly 25 per cent of staff reporting unwanted sexual behaviour from the public last year. According to the survey findings, 3.84 per cent of staff also encountered unwanted sexual behaviour from their colleagues. Dr Navina Evans, Chief Workforce, Training and Education Officer, described the survey results as "very distressing" and said that "such conduct should not be tolerated in the NHS." On the positive side, more NHS workers reported being happier at work and experiencing less burnout than before. Over half of the participants stated they look forward to coming to work, the highest number since 2020, as per the NHS. Dr Evans attributed this improvement to initiatives such as flexible working hours, clinical support squads to help menopausal women at work, and human resources stay advocates.